Study of the pharmacokinetics of a new sidnonymine derivative in rabbits with various routes of administration

Relevance. The search for vasodilating agents that predominantly accumulate in brain tissues is an urgent task. One of the drug candidates with cerebral vasodilating activity is BBP2023 a derivative of sydnonymine.

Objective. A comparative assessment of the pharmacokinetics of BBP2023 in rabbits after a single administration via different routes.

Methods. Experiments were performed using a crossover design on 8 rabbits. The rabbits received a single dose of BBP2023 at 2.0 mg/kg as an oil emulsion intragastrically and rectally, and as an aqueous DMSO solution intravenously and intramuscularly. Blood samples were collected from the marginal ear vein at specific time points. The quantitative determination of BBP2023 and its metabolites in blood plasma was performed using HPLC-MS/MS.

Results. It was found that the highest bioavailability values are achieved with intramuscular administration (97.4 %). With intragastric and rectal administration, this indicator averaged 46.1 and 15.3 %, respectively. The maximum concentration of BBP2023 in blood plasma is reached on average 5 minutes after intragastric administration and averages 0.620 μg/ml; the half-life value averages 1 hour. The maximum concentration of the active metabolite BBP2023 A in blood plasma after intragastric administration is detected on average after 25 minutes and is 0.076 μg/ml.

Conclusion. The pharmacokinetics of the active pharmaceutical substance of drug candidate BBP2023 was studied in rabbits. The results obtained were used for the subsequent selection of the optimal finished dosage form and route of administration.

1. Sanap SN, Bisen AC, Kedar A, et al. Recent Update on Pharmacokinetics and Drug Metabolism in CNS-based Drug Discovery. Curr Pharm Des. 2023;29(20):1602-1616. doi: 10.2174/1381612829666230707121415.

2. Llwyd O, Fan JL, Müller M. Effect of drug interventions on cerebral hemodynamics in ischemic stroke patients. J Cereb Blood Flow Metab. 2022 Mar;42(3):471-485. doi: 10.1177/0271678X211058261.

3. Türkeş C, Demir Y, Beydemir Ş. Some calcium-channel blockers: kinetic and in silico studies on paraoxonase-I. J Biomol Struct Dyn. 2022 Jan;40(1):77-85. doi: 10.1080/07391102.2020.1806927.

4. Dadasheva MN, Zolotovskaya IA, Gorenkov RV, et al. Evaluation of the efficacy and tolerability of naftidrofuryl in the therapy of chronic cerebral ischemia. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):38-43. (In Russ.). doi: 10.14412/2074-2711-2021-1-38-43.

5. Pan X, Lei Z, Chen J, et al. Blocking α1 Adrenergic Receptor as a Novel Target for Treating Alzheimer's Disease. ACS Chem Neurosci. 2024 Sep 26. doi: 10.1021/acschemneuro.4c00411.

6. Panda PK, Ramachandran A, Panda P, Sharawat IK. Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocrit Care. 2022 Aug;37(1):314-325. doi: 10.1007/s12028-022-01499-y.

7. Fumanal Idocin A, Specklin S, Taran F. Sydnonimines: synthesis, properties and applications in chemical biology. Chem Commun (Camb). 2025 Apr 11;61(31):5704-5718. doi: 10.1039/d5cc00535c.

8. Roth L, Van der Donckt C, Emini Veseli B, et al. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. Vascul Pharmacol. 2019 Jul-Aug;118-119:106561. doi: 10.1016/j.vph.2019.05.001.

9. Popov NS, Balabanyan VYu, Baranov MS. Development and validation of HPLC-MS/MS method for molsidomine quantitation in various tissues of rats. Problems of biological, medical and pharmaceutical chemistry. 2023;26(4):32-42. (In Russ.). doi: 10.29296/25877313-2023-04-06.

10. Jeong KH, Lee E. A Systematic review on drug safety for molsidomine, nicorandil and trimetazidine. Korean Journal of Clinical Pharmacy. 2016;26(2):172-180.

11. Popov NS, Gavrilenko DA, Baranov MS, Balabanyan VYu. Development of a method for quantitative determination of nitric oxide (NO) in rat tissues based on high-performance liquid chromatography and mass spectrometry. Pharmacy & Pharmacology. 2024;12(1):49-62. (In Russ.). doi: 10.19163/2307-9266-2024-12-1-49-62.

12. Popov NS, Balabanyan VYu, Kolgina NYu, et al. Quantitative determination of cyclic guanosine monoposphate (c-GMP) in rat tissues using liquid chromatography and tandem mass spectrometry. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2023;(3):28-38. (In Russ.). doi: 10.37489/2587-7836-2023-3-28-38.

13. Popov NS, Baranov MS, Balabanyan VYu. Targeted study of the pharmacokinetics of lead compounds from the sydnonymine group as a basis for creating vasodilators with predominantly central action. Translâcionnaâ medicina. 2024;11(S2):112. (In Russ.).

14. Popov NS, Terekhov VM, Baranov MS. In vivo assessment of the role of liver metabolism in sydnone imine biotransformation. Vestnik RSMU. 2025;(3):50-57. (In Russ.). doi: 10.24075/vrgmu.2025.026.

15. Rules for conducting bioequivalence studies of medicinal products within the Eurasian Economic Union (approved by Decision No. 85 of the Council of the Eurasian Economic Commission dated November 3, 2016). (In Russ.). https://www.consultant.ru/document/cons_doc_LAW_207405/

16. Guidelines for conducting preclinical studies of medicinal products. Part one. Moscow: Grif and K, 2012 (In Russ.)